FDA Approves RAPIBLYK® for Pediatric Supraventricular Tachycardia Treatment

A significant advancement in pediatric cardiovascular care is on the horizon as AOP Health US, LLC announces FDA approval for RAPIBLYK® (landiolol) in treating supraventricular tachycardia (SVT) in patients younger than 18 years. Previously available only for adults, this expanded approval positions RAPIBLYK® as the first therapeutic option for pediatric SVT in the U.S., potentially transforming acute care management for this demographic.

Supraventricular tachycardia, characterized by an abnormally rapid heart rhythm, necessitates precise and rapid treatment, especially in critical care settings. Supported by robust findings from the LANDI-PED study, which indicated a significant reduction in ventricular rates among 60 pediatric patients, this FDA approval underscores a pivotal moment for AOP Health US. As a selective beta-1 adrenergic receptor blocker, RAPIBLYK® offers the benefits of ultra-short action, enabling quick initiation and cessation of its effects. This makes it particularly suitable for dynamic acute care scenarios, allowing healthcare providers both accuracy and control in managing heart rates. John Kimmet, General Manager of AOP Health US, acknowledges the importance of this development in enhancing the options available for managing complex cardiovascular conditions.

With RAPIBLYK® now approved for pediatric use, AOP Health US is poised to significantly impact cardiovascular treatment paradigms in the United States. This milestone not only broadens treatment choice for healthcare professionals but also highlights AOP Health US’s commitment to addressing unmet needs in the medical community.